| |
|
|
|
|
|
|
|||
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2339-2348. Prepublished online as a Blood First Edition Paper on June 22, 2006; DOI 10.1182/blood-2006-02-004291.
NEOPLASIA Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculatureFrom the Departments of Pathology and Molecular Cell Biology, Angiogenesis Laboratory, Research Institute for Growth and Development (GROW), Maastricht University, Maastricht, The Netherlands; and the Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN.
Crucial to designing angiostatic and vascular targeting agents is the identification of target molecules. Because angiogenesis is not limited to pathologic conditions, careful evaluation of putative therapeutic targets is warranted to prevent adverse effects associated with impaired physiologic angiogenesis. To identify tumor-specific angiogenesis markers, we compared transcriptional profiles of angiogenic endothelial cells isolated from malignant and nonmalignant tissues with those of resting endothelial cells. We identified 17 genes that showed specific overexpression in tumor endothelium but not in angiogenic endothelium of normal tissues, creating a therapeutic window for tumor vasculature-specific targeting. Antibody targeting of 4 cell-surfaceexpressed or secreted products (vimentin, CD59, HMGB1, IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. Our results demonstrate the usefulness of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||